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ABSTRACT 
Patients with asthma suffer from reversible airway obstruction accompanied by airway 
hyperresponsiveness (AHR). Airway smooth muscle (ASM) is central to bronchoconstriction and 
AHR and is therefore the target of existing and potential new therapies for asthma.  
Activation of bitter taste sensing type 2 receptors (TAS2Rs) on ASM was recently suggested to induce 
bronchorelaxation by a novel mechanism. Therefore, the first aim of this thesis was to determine the 
potential of TAS2Rs (and their respective agonists) as possible therapeutic targets on ASM. A 
secondary aim of this thesis was to assess whether inflammation induced by IL-13 can alter ASM 
function in intact human airways. 
The methodology used in this thesis mainly involved the study of isometric contractions and 
relaxations in smooth muscle preparations from guinea-pigs and humans. The measurement of 
intracellular Ca
2+
 and analyses of mRNA expression following interventions (cytokines/siRNA) was 
performed in cultured ASM cells.  
Defined TAS2R agonists including chloroquine, denatonium, dextromethorphan, noscapine and 
quinine were found to strongly relax guinea pig trachea, pre-contracted by muscarinic agonists. 
Although the TAS2R agonists were less potent bronchorelaxants than β2-adrenoceptor agonists, they 
were equally (or more) efficacious following stronger pre-contractions. Chloroquine relaxed antigen-
induced contractions, whereas denatonium failed to relax other types of pre-contractions. TAS2R 
agonists were shown to induce relaxation via distinct mechanisms that do not involve conventional 
pathways. 
Human pulmonary arteries, expressing TAS2R mRNA, were relaxed by chloroquine, 
dextromethorphan and noscapine, indicating that TAS2R agonists also affect vascular smooth muscle 
function. In guinea pig aorta, TAS2R agonists elicited relaxations following noradrenergic pre-
contractions, independently of the endothelium, BK or L-type Ca2+ channels. Again, responses 
towards TAS2R agonists were shown to be dependent on the agents used for pre-contraction. Studies 
in guinea pig taenia coli demonstrated antagonism by denatonium and quinine at α-adrenoceptors.  
In human ASM cells, TAS2R mRNA expression was decreased by TNFα and glucocorticoids, and 
increased following 24-48 hours of serum-deprivation. Chloroquine, dextromethorphan, noscapine 
and quercetin induced relaxation of intact human airways, but differentially inhibited histamine-
induced intracellular Ca
2+
 mobilisation. The siRNA-induced decrease of TAS2R14 mRNA could not 
prevent quercetin-mediated inhibitions in human ASM cells. 
In human small airways, IL-13 induced a 2.5-3.1-fold increase in the potency of carbachol and 
histamine contractions, without affecting their amplitude. In addition, IL-13 impaired relaxant 
responses towards salbutamol, but not those towards formoterol, chloroquine and noscapine. IL-13 
increased both the potency and the amplitude of histamine-induced intracellular Ca
2+
 mobilisation in 
human ASM cells. The IL-13-induced hyperreactivity of human bronchi and ASM cells was not 
prevented by the glucocorticoid dexamethasone. 
In summary, although TAS2R agonists exert powerful relaxations in smooth muscle, their effects in 
ASM are not mediated by common pathways. As a consequence, the TAS2Rs may be questioned as a 
target for bronchorelaxation in asthma. On the other hand, IL-13 induces functional remodelling of the 
ASM in human airways that can contribute to AHR. 
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BACKGROUND 
1.1 ASTHMA 
Asthma is a common chronic and heterogeneous disease of the airways that with a wide 
prevalence, depending on the population examined (1-18%),  affects more than 300 million 
people worldwide [1]. The prevalence of asthma continues to increase as a consequence of 
societies adopting Western lifestyles and becoming urbanized [2, 3]. The lifetime prevalence 
for developing asthma (around 35%) is similar to other chronic diseases, such as cancer, 
diabetes and coronary heart disease [4]. However, in comparison to other chronic diseases, 
asthma develops much earlier in life, often during childhood, which causes life-long suffering 
and despite a relatively low mortality, makes it a substantial socioeconomic burden [1, 4, 5].  
Individuals with asthma suffer from recurrent episodes of expiratory airflow limitation 
(exacerbations), accompanied by airway hyperresponsiveness. These periods of airway 
obstruction result in symptoms of wheeze, shortness of breath, chest tightness and/or cough, 
that resolve either spontaneously or following pharmacological treatment [1]. Airway 
inflammation and airway remodelling drive the pathophysiology of the disease by inducing 
airway smooth muscle contraction, increasing mucus production, airway oedema and airway 
wall thickening [6]. Exacerbations represent acute worsening of asthma that can lead to 
hospitalization. These exacerbations are predominantly triggered by viral infections, but 
dependent on the phenotype of the asthma, also by allergens, pollution and pregnancy [7, 8].  
The guidelines for the treatment of asthma are described in a five-step protocol  by the Global 
Initiative for Asthma consortium and focus on the control of symptoms, the prevention of 
exacerbations and decline in lung function, as well as minimizing the risk of side-effects [1]. 
Asthma management is achieved through the use of controller medications that affect the 
airway inflammation, and reliever therapies that reverse airway obstruction and can be used 
when symptoms of asthma worsen. 
The first step of the treatment regime for asthma includes the as-needed use of short-acting β-
adrenoceptor agonists (SABAs). However, as SABAs only facilitate symptom control and do 
not treat inflammation, patients with mild asthma generally receive low-doses of inhaled 
glucocorticosteroids (step 2). Leukotriene synthesis inhibitors or receptor antagonists can be 
considered as alternative first-line or add-on therapy when side-effects develop towards 
glucocorticoids, or when patients prefer oral medications. In case of moderate asthma, long-
acting β2-adrenoceptor agonists (LABAs) can be added to the regime (step 3), together with 
an increased dose of inhaled glucocorticoids (step 4). Add-on therapy by tiotropium, oral 
glucocorticoids or monoclonal antibodies against IgE can be used in patients with severe 
asthma that experience symptoms despite using high doses of inhaled glucocorticoids and 
LABA agonists (step 5). Moreover, improving adherence to therapy and instruction of 
inhalation technique, can promote clinical outcome [9, 10]. 
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1.2 PATHOPHYSIOLOGY 
1.2.1 Heterogeneous disease 
Asthma is often considered to be an allergic, T-helper 2 (Th2)-type dependent inflammation, 
as bronchial biopsies and/or bronchoalveolar fluid from asthmatics were characterized by 
higher numbers of CD4
+
 lymphocytes, eosinophils and mast-cells [11-13]. This has 
encouraged studies of Th2 inflammation and has provided us with a reasonable understanding 
of how Th2 inflammation can contribute to the features of allergic asthma (paragraph 1.2.3). 
Nonetheless, asthma is a heterogeneous disease that includes a large population of patients 
that do not display a typical Th2-type or eosinophilic inflammation [14]. Ongoing studies 
have started to define other specific phenotypes (e.g. neutrophilic, late-onset eosinophilic) on 
the basis of physiological, clinical and biological features [15-17]. However the mechanisms 
of their contribution to asthma remain poorly defined and are therefore not discussed in this 
thesis.  
1.2.2 Epithelium 
The respiratory epithelium consists of specialized columnar ciliated epithelial cells, mucus-
producing goblet cells and surfactant-secreting Clara cells, that  through tight junctions form 
an impermeable physical barrier [18, 19]. This barrier is the first line of defence of the 
airways against potential threats, such as microbes, viruses, pollutants and allergens that are 
present within our environment. Disruption of this barrier function has been suggested as a 
cause of asthma, as this would increase the exposure of the immune system to potential 
threats [20]. 
Epithelial cells can also modulate immune responses, as they express pathogen-recognition 
receptors and produce several lipid mediators, growth-factors, chemokines and cytokines 
[21]. Epithelial cells can also provide co-stimulatory signals for dendritic cell activation, 
thereby increasing allergen sensitization [18, 22]. Moreover, epithelial damage, as a 
consequence of viral infections and/or pollutants, induces the production of TSLP, IL-25 and 
IL-33. These cytokines can drive asthma pathology in the absence of allergens, as they can 
directly activate the adaptive immune system via innate lymphoid cells [23, 24].  
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1.2.3 Airway inflammation – Th2 type  
Naïve T-cells differentiate, following antigen presentation by dendritic cells, into Th2 cells 
that start to produce the typical Th2 cytokines; IL-4, IL-5 and IL-13. IL-4 and IL-13 induce 
the immunoglobulin class-switching of B-cells resulting in the synthesis of IgE, whereas IL-5 
contributes to the recruitment and survival of eosinophils. In addition, Th2 cytokines facilitate 
the recruitment and maturation of mast cells. Re-exposure to allergen can activate mast cells 
via cross-linking with allergen-specific-IgE bound to the FcγR1 receptor on the cell 
membrane. The subsequent release of spasmogenic (e.g. histamine, cysteinyl-leukotrienes 
and prostanoids) and inflammatory mediators (TNFα and IL-13) from mast cells, induces 
bronchoconstriction, increased vascular permeability, mucus hypersecretion and further 
recruitment of inflammatory cells [6].  
Chronic inflammation can develop as a consequence of continuous or repetitive allergen 
exposure. Ultimately, this leads to an extensive inflammatory environment, in which different 
types of adaptive immune cells (Th2, Th17, Treg), granulocytes (eosinophils, mastcells, 
neutrophils) and structural cells (epithelial cells, fibroblasts, airway smooth muscle cells) 
interact with each other, thereby inducing structural damage of the airways [6].       
1.2.4 Airway remodelling 
Airway remodelling describes the structural changes of the airways that develop upon tissue 
damage and repair. The structural changes that can be observed in asthma include; a loss of 
epithelial integrity, goblet cell metaplasia, subepithelial fibrosis due to matrix deposition, 
increased vascularity and as a consequence of hyperplasia/hypertrophy, increased airway 
smooth muscle mass [25, 26]. This airway remodelling results in increased mucus production 
and as a consequence of increased airway smooth muscle mass, in a thicker airway wall that 
presumably increases airway narrowing [27]. Airway remodelling was thought to be the 
consequence of chronic inflammation, however studies have shown that the induction of 
bronchoconstriction by itself, in the absence of inflammation can also induce airway 
remodelling [28].  
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1.3 AIRWAY HYPERRESPONSIVENESS 
Airway hyperresponsiveness (AHR) is a key feature of asthma that is defined by excessive 
airway narrowing following physical (cold air, exercise), chemical (pollutants, tobacco 
smoke) or pharmacological (methacholine, histamine) stimuli that normally have little, or no, 
effect in healthy individuals [29, 30].  
AHR can be clinically assessed by bronchial provocations with direct or indirect stimuli [29, 
31]. Direct stimuli (e.g. histamine, cysteinyl leukotrienes and methacholine) induce a decline 
in lung function via an immediate constriction of the airway smooth muscle. This form of 
hyperresponsiveness is characterized by both an increased sensitivity (potency) and a greater 
maximal response (amplitude) to bronchoconstrictors [31]. On the other hand, indirect stimuli 
(e.g. mannitol, allergen or exercise) constrict the airways through intermediate pathways; 
most often via the release of spasmogens from mast cells, but some indirect stimuli may also 
cause neuronal activation [29].  
It is apparent that AHR includes both a variable and a persistent component [29, 32]. The 
variable component of AHR is inducible and is considered to reflect the acute degree of 
airway inflammation, which is therefore better represented by bronchoprovocations to 
indirect stimuli [33, 34]. On the other hand, AHR to direct stimuli persists in the absence of 
inflammation and despite the improvement achieved by the long-term use of glucocorticoids 
[35-37]. This persistent component of AHR is therefore thought to be a consequence of 
airway remodelling, but the precise mechanisms remain undefined [29, 32]. Nonetheless, as 
AHR to direct stimuli reflects constriction of the airway smooth muscle, it speaks for the 
importance of a decreased airway lumen diameter, increased airway smooth muscle mass and 
altered intrinsic/mechanic properties of the airway smooth muscle itself [29].  
1.4 SMOOTH MUSCLE 
Smooth muscle consists of spindle-shaped, single-nuclear, non-striated cells that cannot be 
voluntary controlled. Smooth muscle can be found throughout the body in the walls of hollow 
organs, such as airways, blood vessels and intestines, where its primary function is to regulate 
the flow of air, circulation of blood or peristaltic movement via contraction and relaxation 
[38].  
Airway and vascular smooth muscle are organized as multi-unit (visceral) smooth muscles in 
which each smooth muscle cell is separately innervated. On the other hand, single-unit 
muscles, such as the intestinal and detrusor smooth muscle, contain more gap-junctions and 
less neuronal innervations, which promotes fluctuations of membrane potentials and 
myogenic activity [39]. Furthermore, variations in excitation-contraction coupling as well as 
heterogeneity in the distribution of ion-channels and receptors, causes the response to a 
certain hormone, neurotransmitter or pharmacological agent to differ between smooth 
muscles [40].     
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1.5 AIRWAY SMOOTH MUSCLE 
In humans, the entire respiratory tree from the trachea to the smaller airways is circumscribed 
by airway smooth muscle.  Historically, the airway smooth muscle has solely been 
considered an effector cell-type in asthma, which causes airway narrowing as a consequence 
of spasmogen release from mast cells and nerves, and an impaired release of epithelium-
derived relaxing factors. However, the introduction of pharmacological strategies that can 
prevent either the actions of spasmogens (e.g. cysteinyl leukotrienes) or facilitate 
bronchorelaxation (β2-adrenoceptor agonists) has proven the importance of the airway 
smooth muscle as a therapeutic target for asthma.  
This traditional view has been changing and the airway smooth muscle is  becoming, in 
addition to its contractile function, acknowledged for its active contribution to the 
development of asthma [41, 42]. Accordingly, the airway smooth muscle can produce a 
variety of growth factors, chemokines and cytokines [43] that can promote the recruitment 
and survival of inflammatory cells, such as mast cells [44]. Moreover, airway smooth muscle 
cells from asthmatics exhibit increased synthetic functions [45], as a consequence of an 
altered extracellular matrix [46, 47] and the variety of mediators that are released during 
inflammation [48, 49]. These increased synthetic functions may contribute to hyperplasia and 
hypertrophy, and the increased airway smooth muscle mass that are observed in patients with 
asthma [50, 51]. 
The airway smooth muscle has, because of the increased sensitivity of the airways to direct 
constrictors of the airway smooth muscle, also logically been linked to AHR [30, 42, 52]. 
However, attempts intended to define whether the mechanical and/or intrinsic properties are 
changed in asthmatic airway smooth muscle has provided conflicting results [30, 52-54]. On 
one hand, experimental observations suggest that inflammatory mediators (e.g. TNFα and IL-
13) can directly alter the intrinsic properties of the airway smooth muscle and therefore 
induce hyperreactivity [55, 56]. These investigations have however been primarily conducted 
in airway smooth muscle cell cultures and in airways from animals. The importance of the 
modulation of airway smooth muscle function by inflammatory mediators remains to be 
confirmed in intact human airways, which will be part of the scope of this thesis.      
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1.6 AIRWAY SMOOTH MUSCLE CONTRACTION 
Airway contraction is induced via a consecutive series of signalling events that encompass 
the excitation-contraction coupling of the airway smooth muscle, which is initiated by the 
binding of spasmogens (e.g. histamine and carbachol) to their respective G-protein coupled 
receptor (Gαqβγ) on the cell-membrane. This protein complex is activated upon agonist 
binding which, via GTP, results in a conformational change of the receptor that causes the 
dissociation of the Gαq and Gβγ subunits. The Gαq unit activates membrane-bound 
phospholipase-Cβ (PLCβ) that promotes the hydrolysis of phosphatidylinositol 4,5-
biophosphate (PIP2) and results in the formation of diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3). DAG activates protein kinase C (PKC), whereas IP3 induces Ca
2+
 release 
from the sarcoplasmic reticulum (SR) via the IP3 receptor [57, 58].  
The release of Ca
2+ 
into the cytosol triggers the opening of other IP3 and ryanodine (RYR) 
channels on the SR resulting in a further increase in intracellular Ca
2+
. The levels of 
intracellular Ca
2+
 can also be raised by entry of extracellular Ca
2+ 
via the opening of receptor-
operated channels, store-operated Ca
2+
 channels or voltage-dependent Ca
2+ 
channels [57, 59, 
60]. Together, these processes induce oscillations of intracellular Ca
2+ 
that via calmodulin, 
facilitate the activation of myosin light chain kinase, resulting in phosphorylation of myosin 
light chains. This enables cross-bridge cycling between actin and myosin ultimately resulting 
in contraction of the airway smooth muscle [57, 58, 61].  
In addition, contractile agonists can increase the sensitivity of airway smooth muscle towards 
Ca
2+
. This process of Ca
2+ 
sensitization is suggested to be regulated by PKC and Rho kinase 
(ROCK), that decrease the reversal of myosin light chain phosphorylation by inhibiting 
myosin light chain phosphates [57, 58, 61]. Importantly, each contractile agonist induces a 
unique contraction of the airway smooth muscle, as contractile agonists have specific and 
distinct effects on Ca
2+
 mobilisation and sensitisation. In this context, the signalling of an 
agonist is determined by several factors, including the binding properties (e.g. duration of 
onset), receptor regulation (e.g. uncoupling or internalization), the G-protein (different α and 
βγ subunits) and compartmentalization [58].   
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1.7 AIRWAY SMOOTH MUSCLE RELAXATION 
Reversal of bronchoconstriction through airway smooth muscle relaxation is an important 
strategy for the treatment of acute symptoms of asthma, and the mechanism of action of 
reliever therapies such as β2-adrenoceptor agonists. Agonists (e.g. salbutamol, formoterol and 
salmeterol) of β2 adrenoceptors, as well as prostaglandin E2 via EP2 and EP4 receptors, 
activate the Gs family of G-protein-coupled receptors. Agonist binding to the Gαsβγ-complex 
results in the dissociation of the Gαs and Gβγ subunits. The Gαs subunit induces membrane-
bound adenylyl cyclase to catalyse the formation of cyclic 3´-5´- adenosine monophosphate 
(cAMP), which can activate protein kinase A (PKA) and exchange protein activated by 
cAMP (Epac) [57, 62]. 
These down-stream effectors of cAMP reduce Ca
2+ 
oscillations through inhibition of IP3 
signalling and a decrease in Ca
2+ 
sensitization. These effects reduce the phosphorylation of 
myosin light chains and thus facilitate airway smooth muscle relaxation [57, 62]. The 
individual contributions of the down-stream effectors of cAMP remain incompletely 
understood. Recent studies have demonstrated that the acute relaxations by β2 adrenoceptor 
agonists are dependent on PKA and not Epac activation [63], implying other physiological 
functions for Epac [64]. 
Airway smooth muscle relaxation can also be achieved through other pathways. Nitric oxide 
(NO), enters the cytosol and induces via guanylyl cyclase the formation of cyclic guanine 
monophosphate (cGMP), which exerts its effects through protein kinase G [57, 65]. However, 
NO, is in comparison to its effects in vascular smooth muscle, a relatively weak relaxant of 
airway smooth muscle [66]. Phosphodiesterase inhibitors like theophylline induce relaxation 
of the airway smooth muscle by preventing the breakdown of the cyclic nucleotides (cAMP 
and cGMP). Relaxation of airway smooth muscle can also be achieved via interaction with 
ion channels [65]. Blockade of voltage-dependent Ca
2+ 
channels (e.g. L-type) prevents the 
entry of extracellular Ca
2+
, thereby limiting the availability of Ca
2+
 for contraction. On the 
other hand, potassium channels, like large-conductance Ca
2+
 activated potassium (BK) 
channels, control membrane potential and upon opening, cause relaxation through 
hyperpolarization [65, 67, 68].  
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1.8 TASTE SENSING TYPE 2 RECEPTORS 
1.8.1 General 
Taste perception in the gustatory system is based on the recognition and distinguishment of 
five unique taste qualities; bitter, sweet, salt, sour and umami. Bitter taste is detected in the 
taste bud regions of the tongue via taste sensing type 2 receptors (TAS2Rs), which belong to 
the family of G-protein coupled receptors [69-72]. The signal transduction of TAS2Rs is 
considered to involve the taste-specific Gα subunit gustducin [73]. Upon activation, 
gustducin induces the induction of intracellular Ca
2+
 via IP3, which is suggested to trigger the 
influx of cations via TRPM5 channels [74]. However, transduction of bitter taste is not 
entirely dependent on these pathways [73, 75].   
TAS2R function is considered to be important in evolution as this class of receptors prevents 
us from the intake of potentially harmful substances, which commonly have a bitter taste 
[76]. The human genome contains 25 different TAS2Rs, a number that differs between 3 and 
50 among other species [77, 78]. However, TAS2Rs can, despite their relatively low number, 
recognize an enormous range (> 1000) of  structurally diverse bitter compounds [76].  
Structural screenings in TAS2R-overexpressing human embryonic kidney (HEK) cells using 
bitter compounds demonstrated that TAS2R agonists display a relatively low affinity for the 
TAS2Rs, as high micromolar concentrations were needed to activate the TAS2Rs [78]. 
However, most TAS2R agonists could activate multiple TAS2Rs, suggesting that the 
perception of a bitter taste by the gustatory system is determined by a complex 
interaction/activation profile of the TAS2R agonists.  
1.8.2 Extra-oral functions 
In addition to their function in the oral cavity, TAS2Rs have been implicated in several extra-
oral functions within other organs of the human body, including the respiratory [67, 79-82], 
gastro-intestinal [83, 84], cardiovascular [85, 86] and reproductive system [87].  
In the airways, TAS2R expression was first described in respiratory epithelial cells, where 
they sense and facilitate clearance of chemical and bacterial irritants  by increasing ciliary 
beat frequency [79-81, 88]. The involvement of TAS2Rs in such a role was confirmed in 
patients with polymorphisms for TAS2R38, a receptor known to be activated by acyl-
homoserine lactone quorum-sensing molecules from gram-negative bacteria, as these patients 
were more susceptible to infections with Pseudomonas Aeruginosa [80]. In relation to 
respiratory disease, a transcriptome analysis on blood leukocytes revealed that TAS2R 
expression was increased in children with severe asthma, which suggests a possible role for 
TAS2Rs in asthma [82]. 
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Interestingly, TAS2Rs were also found to be expressed on airway smooth muscle and 
implicated in bronchorelaxation, as TAS2R agonists induced strong relaxations of airway 
smooth muscle preparations [67]. Moreover, TAS2R agonists were shown to be more 
protective than β2-adrenoceptor agonists in an in vivo mouse model of allergic asthma [67]. 
This first study proposed a new concept for airway smooth muscle relaxation, as TAS2R 
agonists were suggested to induce an opening of BK channels through localized Ca
2+
 
signalling, that resulted in hyperpolarization of the cell membrane [67]. These findings have 
encouraged both ourselves and others to define the effects of TAS2Rs and TAS2R agonists in 
airway smooth muscle. Thus, the effects and mechanisms of these agonists is a central theme 
in this thesis. 
1.8.3 TAS2R agonists 
Most studies that have described extra-oral functions of TAS2Rs base their conclusions, in 
the absence of antagonists and gene-deficient animals, on the expression of TAS2Rs and the 
observed effects of TAS2R agonists in a certain tissue. Although TAS2R agonists exhibit 
well-defined activity at TAS2Rs [78], their use at relatively high concentrations increases the 
possibility for  interactions with other targets, such as receptors and ion-channels. A summary 
of reported non-TAS2R interactions for the different TAS2R agonists used in this study is 
presented in Table 1.  
TAS2R agonists Pathway of interaction Actions Ref 
Chloroquine α-adrenoceptors Antagonist [89] 
 Muscarinic receptors Antagonist [90, 91] 
Denatonium Delayed rectifier K
+
 channels  Blocker [92] 
Dextromethorphan Opioid receptors Agonist [93, 94] 
 NMDA receptors Antagonist [95, 96] 
 Sigma receptors Agonist [97] 
 Voltage-dependent Ca
2+
 channels Blocker [98] 
Noscapine Opioid receptors Agonist [99] 
Quinine α-adrenoceptors Antagonist [100, 101] 
 Voltage-gated K
+
 channels Blocker [102, 103] 
 
Table 1: Summary of possible interactions between TAS2R agonists and TAS2R-independent  
pathways as reported in the literature.  
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1.9 IL-13 
IL-13 is a typical Th2 type cytokine, which in addition to being produced by Th2 cells, is 
produced by many other inflammatory cells including mast cells, eosinophils and innate 
lymphoid cells. IL-13 plays a prominent role in the development of allergic inflammation, as 
it has been shown to induce eosinophilic inflammation, mucus hypersecretion and AHR [104-
106]. IL-13 can bind to the IL-4Rα, IL-13Rα1 and IL-13Rα2 receptors [107]. The binding to 
a heterodimer of the IL-13Rα1 and IL-4Rα chains seems to be critical for the majority of 
effects mediated by IL-13 [105, 107, 108]. Activation of the IL-13Rα1/IL-4Rα dimer 
receptor complex induces the phosphorylation of STAT-6 via activation of JAK, which then 
translocates to the nucleus and promotes the transcription of IL-4/IL-13 responsive genes 
[107, 109].     
The IL-13Rα2 receptor, which exhibits higher affinity for IL-13, was initially thought to be a 
decoy receptor, as it lacked a transmembrane signalling domain [107]. However, this concept 
has been questioned [110], and the contribution made by IL-13Rα2 to allergic inflammation 
remains therefore unclear. 
Interestingly, from initial mouse studies, it became apparent that IL-13 caused the induction 
of AHR independently of IgE and eosinophilia, which suggested that IL-13 induced AHR via 
a direct effect on the airway smooth muscle [104, 111]. Indeed, airway smooth muscle cells 
were found to express IL-13 receptors and display STAT-6 activation upon IL-13 stimulation 
[112]. Functionally, IL-13 has been shown to impair responsiveness towards β2-adrenoceptor 
agonists in both airway smooth muscle cells [112] and isolated animal airways [113]. 
Moreover, IL-13 increases the amplitude of airway smooth muscle contractions in mouse and 
rabbit airways [113-117]. These effects suggest that IL-13 can affect airway smooth muscle 
function and therefore has the potential to contribute to the development of airway 
hyperresponsiveness.  
Currently, several new strategies attempt to block the effects of IL-13 in asthma [118-120]. 
However, in the context of airway smooth muscle, the effects of IL-13 have only sparsely 
been investigated in intact human airways [121].  
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2 MATERIALS AND METHODS 
This section will provide a summary of the methods used in this thesis.  Detailed descriptions 
of these methods can be found in the material and method sections of the different 
publications and manuscripts.  
2.1.1 General 
The initial studies in this thesis were conducted using isolated airway or vascular smooth 
muscle preparations from guinea pigs (Paper I and II), mice (Paper II) and humans (Paper 
II, III and IV). Further studies designed to investigate the regulation of TAS2Rs (Paper III) 
and the mechanisms underlying the effects of TAS2R agonists (Paper III) and IL-13 (Paper 
IV) were conducted using human airway smooth muscle cells.  
2.1.2 Animals 
All studies including animals (Paper I and II) were conducted in accordance with the ethical 
permits provided by the Swedish animal experimentation ethical review board. Guinea pigs 
(Dunkin-Hartley) and mice (C57BL/6) were obtained from Harlan and housed according a 12 
hour light/dark cycle and were given food and water ad libitum. Guinea pigs were sacrificed 
by an overdose of pentobarbital or CO2, whereas mice were killed by cervical dislocation. 
The heart-lung package was immediately removed, along with eventual other smooth 
muscles, and placed in ice-cold Krebs-Henseleit solution until further dissection.   
2.1.3 Human lung tissue 
The use of human lung tissue in paper II, III and IV was approved by the Stockholm ethical 
review board 2010/181-31/2 and all patients provided written informed consent beforehand. 
Macroscopically healthy human lung tissues were obtained from patients undergoing 
lobectomy for adenocarcinoma and other indications, and after surgery were immediately 
placed into ice-cold Krebs Henseleit buffer.   
Human airways and pulmonary arteries (inner diameter < 2 mm) were identified in the lung 
specimens and distinguished from each other by their visual appearance under the 
microscope. Human bronchi were identified based on the presence of mucus and their 
transparent colour, as the airway wall is much thinner and less white than the vessel wall. 
Airways and arteries were then dissected out with the help of a thin smooth fishing line that 
was used to determine the direction of the airways and arteries within the tissue (Figure 1).  
 
 
 
 
Figure 1: Human lung tissue 
demonstrating the identification of the 
human small bronchus (Br) and the 
pulmonary artery (PA). The black 
fishing line has a diameter of 0.25 
mm.  
PA 
Br 
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2.1.4 Organ culture  
Human bronchi that are used immediately after isolation from human lung tissue exhibit a lot 
of spontaneous activity, which makes these preparations difficult to work with. A common 
way to overcome this is by storing the isolated bronchi overnight at 4
ᵒ
C in Krebs Henseleit 
buffer. Although this procedure removes spontaneous tone, the rate of survival, particularly 
of the smaller human bronchi was relatively low.  
To increase utility of this tissue, isolated human bronchial segments were transferred to 
culture plates containing DMEM medium supplemented with penicillin and streptomycin and 
placed into organ culture at 37
ᵒ
C in a humidified incubator at 95% CO2 and 5% O2 [122]. 
Every day, segments were transferred to fresh DMEM medium. The viability of human small 
bronchi segments was greatly improved by this methodology and the most consistent results 
were obtained from human bronchi that were maintained in this way for 2-4 days.  
This methodology allowed investigations of the effects of inflammatory mediators on airway 
smooth muscle function, a method that was developed earlier to study the influence of 
inflammatory mediators on mouse tracheal smooth muscle [123]. Thus, IL-13 or a vehicle 
control were administrated daily to the culture. For specific purposes, bronchial segments 
could also be re-cultured after an initial assessment of their contractile function (Figure 2). 
 
Figure 2: Schematic scheme of the re-culture assay. 
2.1.5   Organ bath – in vitro pharmacology 
The main methodology used in this thesis involves the measurement of contractions and 
relaxations in isolated smooth muscle preparations in the presence of different 
pharmacological interventions. Smooth muscle preparations were isolated from guinea pig, 
mice and humans and included airway smooth muscle (trachea or bronchi), vascular smooth 
muscle (aorta and pulmonary artery), gastrointestinal smooth muscle (taenia coli and ileum) 
and detrusor smooth muscle. Airway and vascular smooth muscle preparations were used as 
rings, whereas taenia coli [124], longitudinal ileum smooth muscle [125] and detrusor smooth 
were prepared as strips. 
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Following dissection, smooth muscle preparations were mounted in 5-10 ml organ baths or 
myographs filled with Krebs Henseleit buffer that was maintained at a temperature of 37 ºC 
and continuously bubbled with 5% CO2 in O2 to maintain a pH of 7.4. Changes in smooth 
muscle force were detected using an isometric force-displacement transducer linked to a 
Grass polygraph. Responses were displayed using LabChart 7 software.  
Smooth muscle preparations were stretched and equilibrated for (1-2 hours) before the 
assessment of the viability of the smooth muscle preparations using either histamine or 60 
mM of potassium chloride (KCl). The detailed experimental protocols for the different 
research studies can be found in the individual papers.   
2.1.6 Airway smooth muscle cell culture 
Human airway smooth muscle (HASM) cells were commercially purchased from Lonza or 
Promocell and grown in DMEM medium supplemented with 10% fetal bovine serum (FBS) 
and penicillin/streptomycin at 37°C in a humidified incubator. Confluent HASM cells were 
used for gene expression studies or measurements of intracellular Ca
2+
. Stimulation 
experiments were conducted on HASM cells that were growth-arrested for 24-hours in 
serum-deprived medium containing 0.3% FBS. Detailed descriptions of the different 
protocols used can be found in the methods sections of studies III and IV. 
2.1.7 RNA/cDNA isolation and synthesis 
RNA from lysed HASM cells and isolated smooth muscle tissue preserved in RNAlater®, 
was extracted according to the manufacturer’s instructions using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany). To prevent genomic DNA contamination, a DNase step was 
always included. Concentration and purity were assessed using a Nanodrop 3300 
spectrophotometer- 
RNA (320-1000 ng) was transcribed to cDNA using Quantitect® Reverse Transcription kit 
(Qiagen) or High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster 
City, CA, USA).   
2.1.8 Real-time polymerase chain reaction (PCR) 
Real-time PCR was performed using Taqman® primers. All samples were analysed in 
duplicate and in the presence of relevant negative controls (-RT and water). In experiments 
where the levels of expression were reported, gene expression levels were normalized against 
the endogenous control β-actin.  
Changes in mRNA expression in intervention studies (cytokines, siRNA and glucose/serum 
deprivation) were calculated using the 
∆∆
Ct method. Normalization in these studies was 
conducted using the average of three endogenous controls that were individually chosen for 
each experimental set-up.   
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2.1.9 Small interfering RNA (siRNA) 
Our aim was to develop an efficient siRNA transfection protocol in HASM cells that could be 
used to down-regulate the expression of TAS2Rs.  
Airway smooth muscle cells were seeded on day 1 in 6-wells plate at a density of 10
5
 cells 
per well and grown in normal DMEM culture medium. On day 2, the medium was replaced 
with 900 µl DMEM growth medium. Commercially available siRNAs (Qiagen) were mixed 
with 6-12 µl HiPerfect (Qiagen) in Opti-MEM® medium (Life technologies) in a total 
volume of 100 µL. This mixture was vortexed and incubated for 10 minutes at room 
temperature and then added to the cells in a drop-wise fashion. The same procedure was 
repeated on day 3 and cells were harvested for evaluation of mRNA expression on day 4. 
Functional experiments using measurements of intracellular Ca
2+ 
mobilisation were 
conducted on day 5. 
The transfection uptake of siRNA of HASM cells following different amounts of transfection 
reagent (6 and 12 µL) was evaluated using an immunofluorescence technique (Figure 3). 
These studies demonstrated that the uptake of siRNA was improved by increasing the 
concentration of HiPerfect® transfection reagent. The viability and growth of the HASM 
cells was not affected by the transfection reagent. 
 
Figure 3: Relative immunofluorescence 24-hours after transfection of HASM cells transfected with an 
AlexaFluor 488-labeled siRNA.  
The knock-down efficacy of the different transfection protocols was evaluated by examining 
the down-regulation of MAPK1 by RT-PCR, as the positive control siRNA in our 
experiments was directed against MAPK1. Changes in mRNA were compared to negative 
siRNA, which exhibited a similar expression pattern compared to those cells treated with 
transfection reagent only. Repeated transfection using 12 µL of transfection reagent resulted 
in a robust decrease in MAPK1 mRNA (79%; Figure 4). The observed siRNA-induced 
reduction in mRNA is in line with previous reports of similar procedures in HASM cells 
[126]. No attempts were made to further investigate whether this improved efficacy was a 
consequence of the time or the 2
nd
 transfection. For the actual experiments, HASM cells were 
transfected with 40 nM siRNA (Negative) or 4x10 nM (TAS2R14) and 12 µL of transfection 
reagent on two consecutive days.  
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Figure 4: Evaluation of MAPK1 knock-down after different siRNA transfection protocols. Changes in MAPK1 
mRNA expression were compared between HASM cells treated with Allstars-negative or MAPK1 siRNA (40 
nM) using the comparative Ct (2
-∆∆Ct
) method.  Data are presented as means ± SEM.  
2.1.10 Measurements of mobilisation intracellular Ca2+ 
Mobilisation of intracellular Ca
2+
 in HASM cells was measured in studies III and IV for 
different purposes. A detailed description of the dye-loading protocol can be found in the 
method section of study IV. Briefly, HASM cells were detached as usual using 
trypsin/EDTA, incubated at room temperature for thirty minutes in PBS containing 3 μM 
Fluo-4-AM, 0.02% pluronic F-127 and 2.5 μM probenecid. Following a wash with 
probenecid, HASM cells were re-suspended at a concentration of 10
6
 cells per mL in 
Dulbecco’s PBS (DPBS) containing Ca2+ Mg2+, 10 mM glucose and 0.1% BSA. Pluronic F-
127 was used to enhance solubilisation of the dye Fluo-4-AM, whereas probenecid was 
included in the protocol to block the anion transporter and thereby prevent leakage of Fluo-4 
from the cell. Ca
2+
 fluxes were analysed by flow cytometry (LSR Fortessa®). 
In both studies, the baseline mean fluorescence intensity (MFI) was measured for thirty 
seconds, which was followed by the administration of histamine and a subsequent recording 
of ninety seconds. In paper III, HASM cells were pre-incubated in the dark for 5-minutes 
with vehicle or TAS2R agonists before measurements of baseline MFI and the induction of 
intracellular Ca
2+
 by histamine (100 µM). In paper IV, the mobilisation of intracellular Ca
2+
 
following the non-cumulative administration of histamine (0.1-100 µM) was evaluated in 
HASM cells that were cultured for 24-hours in the presence of vehicle, IL-13, dexamethasone 
or dexamethasone and IL-13.    
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Data was analysed using FlowJo X software (Ashland, OR, USA). Histamine-induced 
induction of intracellular Ca
2+
 was presented as a percentile increase from baseline MFI 
(Paper III and IV). In addition, in order to determine potential shifts in potency in paper IV, 
the increases for the individual concentrations of histamine were normalized against the 
maximal induction of Ca
2+
 (100 µM of histamine) within each individual group.  
2.1.11 Enzyme-linked immunosorbent assay (ELISA) 
The production of cAMP and release of PGE2 in the guinea pig trachea upon the 
administration of chloroquine and denatonium, was measured by ELISA in study I. As cAMP 
is an intracellular second messenger with a rapid turnover rate, levels were measured in liquid 
nitrogen snap-frozen guinea pig tracheal rings that were pre-treated with the 
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine [127]. PGE2 levels were determined 
in the organ bath fluid that was collected during different time-points of the relaxant 
responses. Salbutamol (cAMP) and bradykinin (PGE2) were used as positive controls for 
these studies. PGE2 levels were measured using Cayman Chemical’s “Prostaglandin E2 EIA 
kit – Monoclonal” (cat nr 514010.1).  The detection limit was 15 pg/ml with cross-
reactivity’s towards PGE3 (43.0%), 8-iso PGE2 (37.4%), PGE1 (18.7%) and 6-keto PGF1 
(1%), 8-iso PGF2α (0.25%) and 13,14-dihydro-15-keto PGE2 (0.02%). cAMP levels were 
measured by Cayman Chemical’s “Cyclic AMP EIA kit” (cat nr 581002). The detection limit 
was 3 pmol/ml with a cross-reactivity towards cGMP (0.69-1.5%), but not towards AMP, 
ATP and adenosine (<0.01%).  
2.1.12 Calculations and statistics 
In organ bath experiments, contractions were expressed in relation to the tissues own 
maximal response or a reference contraction and for specific purposes in paper IV as 
absolute contraction in mN. Relaxations were presented as a percentile change from pre-
contraction and related to maximal relaxations within the tissue. A non-linear regression 
analysis with a variable slope was used to calculate pEC50 from concentration-response 
curves.  
Statistics and data analysis were performed using GraphPad Prism® software and all data in 
the different studies are presented as mean ± SEM. For comparisons between two groups, a 
Mann-Whitney or paired-t test was used. One-way or two-way ANOVAs were used to 
compare between 3 or more groups, single or two-independent variables respectively. To 
correct for multiple comparisons, Dunnett’s post-hoc test was used for many-to any 
comparisons and otherwise a Bonferroni’s post-hoc test was used. The exact test used for 
specific comparisons is described in the different manuscripts. 
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3 AIMS OF THE THESIS 
 
The overall aim of this thesis was to investigate whether the effects of TAS2R agonists and 
IL-13 on airway smooth muscle could be targets for the development of future asthma 
therapies. 
Specific aims 
o To characterize the effects of TAS2R agonists on the airway smooth muscle function 
in cells and intact rodent and human airways.   
 
o To investigate whether the effects of TAS2R agonists are specific for airway smooth 
muscle, by examining the effects of bitter tastants in vascular and other smooth 
muscle preparations. 
 
o To define the possible mechanism(s) via which TAS2R agonists elicit 
bronchorelaxation. 
 
o To assess the involvement of TAS2Rs in the bronchorelaxation by TAS2R agonists. 
 
o To determine the effect of IL-13 on airway smooth muscle function in relation to 
airway hyperreactivity.  
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4 RESULTS AND DISCUSSION 
4.1 CHARACTERISATION OF EFFECTS TAS2R AGONISTS  
Initial functional experiments demonstrating that airway smooth muscle can be relaxed by 
TAS2R agonists, were primarily conducted in mouse airway smooth muscle [67]. To further 
increase our understanding of the relaxant activities of TAS2R agonists, investigations with a 
broader panel of TAS2R agonists were performed in the guinea pig trachea, a model that 
resembles human airway pharmacology better than murine models [128] 
4.1.1 TAS2R agonist selection 
Guinea pig orthologues for TAS2R1, TAS2R3, TAS2R4, TAS2R10, TAS2R14, TAS2R16, 
TAS2R41 and TAS2R42 were identified using the Ensembl database (ensembl.org). For 
functional characterization of these receptors, TAS2R agonists were selected on the basis of 
their reported activities in TAS2R-overexpressing HEK cells [78] (Table 2). Chloroquine 
was considered to be a specific agonist for TAS2R3, as 1000-fold higher concentrations were 
needed to elicit a response in TAS2R10-overexpressing HEK cells (Table 2). Similarly, 
denatonium was deliberated to selectively activate TAS2R10, as its activity at this receptor 
was 100-fold greater than at TAS2R4, and no orthologues were found for the other TAS2Rs 
that denatonium can activate in HEK cells. 
 
Table 2: Minimal concentrations needed to elicit a positive Ca
2+
 signal in TAS2R-overexpressing 
HEK cells. This information  is based on the work from Meyerhof et al [78]. 
#
Quercetin was recently 
identified as a new agonists for TAS2R14 in the same cellular system, however its activity at other 
TAS2Rs has not yet been determined (nd.). 
4.1.2 Airway smooth muscle  
4.1.2.1 Guinea pig trachea 
To study relaxations, guinea pig tracheal rings were pre-contracted with the muscarinic 
agonist carbachol, followed by the cumulative administration of the TAS2R agonists 
thiamine (TAS2R1), chloroquine (TAS2R3), denatonium (TAS2R10), noscapine 
(TAS2R14), dextromethorphan (TAS2R1&10) or quinine (TAS2R4, 10 & 14). Chloroquine, 
denatonium, dextromethorphan, noscapine, quinine and thiamine all induced relaxation 
following muscarinic pre-contraction of guinea pig trachea (Figure 5). These TAS2R 
agonist-mediated relaxations are in line with observations made in the mouse, where  
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chloroquine, denatonium and quinine were shown to relax methacholine-induced contractions 
[129, 130]. On the other hand, saccharine, an agonist for TAS2R31 that is known to relax 
human bronchi [67], did not elicit relaxations in the guinea pig trachea (Paper I, figure 1G). 
This finding supports the possibility that these agonists exert their effects via TAS2Rs, as the 
receptor for saccharine (TAS2R31) was lacking in the guinea pig genome.      
To further evaluate the potential of TAS2R agonists in settings of relevance to asthma, the 
effects of chloroquine and denatonium were examined following antigen-induced 
contractions of the guinea pig trachea. This contraction is similar to indirect 
bronchoconstriction in humans and is caused by the release of spasmogenic mast cell 
mediators [131]. Denatonium could not reverse antigen-induced contractions in the guinea 
pig trachea (Paper I, figure 4A). Neither could denatonium relax pre-contractions induced 
by the individual components of the antigen response including histamine, cysteinyl-
leukotrienes and U-46619 (TP-receptor agonist) (Paper I, figure 4B-D), indicating that the 
effects of this TAS2R10 agonist are dependent on the type of pre-contraction. Two other 
agonists for TAS2R10, dextromethorphan and quinine, were also unable to relax TP receptor-
mediated contractions (Figure 5).  On the other hand, chloroquine completely relaxed 
antigen-induced contractions (Paper 1, figure 4A), strengthening its potential as an anti-
asthmatic intervention. 
Furthermore, chloroquine, denatonium, dextromethorphan, noscapine and quinine did not 
induce baseline contractions in guinea pig tracheal rings. These experiments were conducted 
in the presence of the cyclooxygenase inhibitor indomethacin, to prevent the development of 
spontaneous tone as a consequence of PGE2 production.   
Figure 5: Cumulative-concentration responses for the TAS2R agonists chloroquine, denatonium, 
dextromethorphan, noscapine and quinine in guinea pig tracheal rings pre-contracted by 100 nM carbachol (○) or 
100 nM U-46619 (●). Data are presented as means ± SEM (n: 4-8).     
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4.1.2.2 Mouse trachea 
In the mouse trachea, chloroquine, denatonium and noscapine elicited relaxations following 
pre-contractions induced by carbachol. These relaxations were also more potent than in 
guinea pig trachea. However, the efficacy and potency of chloroquine- and denatonium-
mediated relaxations were markedly lower following pre-contractions with U-46619 (Figure 
5). Conversely, the potency of noscapine was increased following pre-contraction with U-
46619 in mouse trachea (Figure 6).  
The impact of the type of pre-contraction on TAS2R-agonist mediated relaxations, was also 
supported by studies by Tan and colleagues, who showed that the potency of chloroquine-
mediated relaxations were reduced when mouse airways were pre-contracted by 5-HT [130]. 
In addition, the first study reporting the actions of denatonium, only showed relaxations 
following muscarinic pre-contractions [67].  
  
Figure 6: Cumulative-concentration responses for the TAS2R agonists chloroquine, denatonium and noscapine 
in mouse trachea pre-contracted by carbachol or the TP-receptor agonist U-46619. 
4.1.2.3 Human bronchi 
Investigations in intact human airways demonstrated that the TAS2R agonists chloroquine, 
dextromethorphan, noscapine and the recently identified TAS2R14 agonist quercetin, exerted 
relaxations of both histamine- and carbachol-induced pre-contractions (Paper III, figure 3 
and Paper IV, figure 3). The potency of chloroquine-induced relaxations was almost 10 
fold-greater in human airways compared to the guinea pig trachea, whereas the potency and 
efficacy of dextromethorphan and noscapine were similar. Furthermore, the capacity of these 
agonists to relax pre-contractions other than those caused by muscarinic stimuli, excludes the 
possibility that these TAS2R agonists induce relaxation via antagonism of muscarinic 
receptors.  
4.1.2.4 Summary 
Taken together, our findings in guinea-pig, mouse and human airways clearly indicate that 
TAS2R agonists induce relaxation of airway smooth muscle by distinct mechanisms that are 
probably linked to different components of excitation-contraction coupling in the airway 
smooth muscle.    
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4.1.3 Vascular smooth muscle  
4.1.3.1 Guinea pig aorta 
To assess whether relaxations induced by TAS2R agonists were specific to airway smooth 
muscle, the effects of TAS2R agonists on vascular smooth muscle function were first 
examined in the guinea pig aorta.  
Chloroquine, denatonium, dextromethorphan, noscapine and quinine induced complete 
relaxations in aortic rings pre-contracted with the α1-adrenoceptor agonist phenylephrine. The 
potencies of the relaxations were similar for the different TAS2R agonists tested in the guinea 
pig aorta. Moreover, the potencies of chloroquine-, noscapine- and quinine-mediated 
relaxations were greater in the aorta compared to the guinea pig trachea. The relaxations were 
unaffected by denudation of the endothelium, indicating that TAS2R agonists exert their 
effects directly on the smooth muscle and not via the release of endothelium-derived 
mediators.  
Similar to the airway smooth muscle, TAS2R agonist relaxations in vascular smooth muscle 
were shown to be dependent on the agonists used for pre-contraction. Thus, denatonium, 
dextromethorphan and quinine were unable to relax contractions caused by U-46619 or 
PGF2α (Paper II, figure 1), which corresponds with their inability to relax contractions 
induced by the TP-receptor agonist U-46619 in guinea pig trachea (Figure 5).  
In order to examine the effects of TAS2R agonists on contractions that occur independently 
of G-protein-coupled receptor activation, guinea pig aortic rings were pre-contracted by 
potassium chloride. All TAS2R agonists elicited slow and relatively minor relaxations of the 
depolarisation-induced contractions evoked by potassium chloride (Paper II, figure 1).  
4.1.3.2 Human pulmonary artery 
In order to translate the guinea pig findings to human vascular smooth muscle, the responses 
induced by TAS2R agonists were examined in human pulmonary arteries (HPA). Human 
pulmonary arteries expressed mRNA for TAS2R3, TAS2R10 and TAS2R14, suggesting that 
the receptors for chloroquine, dextromethorphan and noscapine are expressed in HPA (Paper 
II, figure 7). Functional experiments demonstrated that chloroquine, dextromethorphan and 
noscapine induced strong relaxations of phenylephrine-induced contractions. However, when 
HPA rings were pre-contracted by U-46619, the relaxations induced by chloroquine were 
impaired, the effects of dextromethorphan were negligible, whereas the responses to 
noscapine remained equally as strong (Paper II, figure 6). These observations were similar 
to the findings in the guinea pig aorta, indicating that the effects of TAS2R agonists in 
vascular smooth muscle are similar between species. 
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4.1.4 Gastrointestinal smooth muscle  
Contractions in the airway and vascular smooth muscle are primarily induced by the IP3-
driven mobilisation of Ca
2+
 from intracellular stores [132]. On the other hand, the excitation-
contraction coupling in the smooth muscle of the gastrointestinal or urogenital tract is 
different and depends to a greater extent on other Ca
2+
 signalling mechanisms  [40, 132]. 
Therefore, the effects of TAS2R agonists were studied in the ileum and the detrusor smooth 
muscle. This was done in an attempt to provide new information on the mechanism of action 
of the TAS2R agonists.  
Due to the phasic nature of the contractions in ileum and detrusor smooth muscle, the ability 
of TAS2R agonists to inhibit the development of contractions in these preparations was 
examined. Pre-incubation for five minutes with the selected TAS2R agonists chloroquine, 
denatonium, dextromethorphan, noscapine and quinine prevented the development of 
contractions caused by both histamine and acetylcholine in guinea pig ileum longitudinal 
smooth muscle (Figure 7). The TAS2R agonist-mediated inhibitions were, with the 
exception of denatonium-treated segments, reversible after a wash-out period (Figure 7). The 
effects of denatonium in the guinea pig ileum differ from our observations for denatonium in 
the guinea pig trachea, where denatonium did not affect histamine-induced contractions and 
responses were reversible after wash-out. This raises the possibility that denatonium exerts its 
effects in the guinea pig ileum via another pathway.       
 
Figure 7: Cumulative concentration- responses to histamine in guinea pig longitudinal smooth muscle 
preparations before, after 5-min pre-stimulation with the different TAS2R agonists and after wash-out. Data are 
presented as mean ± SEM.   
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Other patterns of inhibitions were observed 
when contractions were mediated by non-
cumulative administrations of PGE2. Thus, 
the PGE2-induced contractions were 
inhibited by dextromethorphan, but not by 
chloroquine, noscapine and quinine 
(Figure 8). In line with previous 
experiments, our experiments with the 
selective EP1 receptor antagonist ONO-
8130 demonstrated that contractions 
induced by PGE2 in the guinea pig ileum were 
mediated by the EP1 receptor [133]. However, 
dextromethorphan-mediated inhibitions were not a 
consequence of EP1 receptor antagonism, as contractions induced by the EP1 receptor agonist 
17-trinor-phenyl-PGE2 in the guinea pig trachea were unaffected by dextromethorphan.  
4.1.5 Detrusor smooth muscle  
The detrusor smooth muscle is a unique smooth muscle preparation in which  contractions are 
induced primarily via membrane depolarization as a result of the opening and closure of Ca
2+
 
and K
+
 channels [132, 134]. The effects of TAS2R agonists were evaluated in detrusor 
smooth muscle, because these channels have been implicated in the relaxations caused by 
TAS2R agonists [67, 135],  
All selected TAS2R agonists (100 µM) enhanced the amplitude of the spontaneous baseline 
activity in guinea pig detrusor smooth muscle (Figure 9A-B). This increase in spontaneous 
activity was, again with the exception of denatonium, completely reversible. These findings 
regarding the  myogenic tone are of particular interest due to the recent suggestion that bitter 
tastants (e.g. denatonium) trigger bladder reflexes via the release of acetylcholine [136]. 
However, our study demonstrated that the TAS2R agonist-induced increases in spontaneous 
activity were resistant to atropine, excluding the possibility that the effect was caused by 
acetylcholine release. Instead, our data suggest that the effects of the TAS2R agonists reflect 
an interaction with a certain family of ion channels, in particular potassium channels [137].       
More distinct effects of the different TAS2R agonists were observed following muscarinic-
mediated contractions, as dextromethorphan profoundly inhibited carbachol-induced 
contractions, chloroquine and noscapine exerted smaller inhibitions, and denatonium and 
quinine were without effect (Figure 9C). On the other hand, the maximal response of 
contractions induced by the purinergic P2X agonist α,β-methylene ATP, were not affected by 
any of the TAS2R agonists (Figure 9D). However, the return to baseline of contractions 
induced by α,β-methylene ATP was more rapid in the presence of dextromethorphan.    
Figure 8: TAS2R agonist-mediated inhibitions 
of contractions by PGE2 in guinea pig ileum 
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Figure 9: Effects of TAS2R agonists in detrusor smooth muscle. A)  Experimental traces of the increased 
spontaneous activity that develops after the administration of TAS2R agonists. B) Compiled data on the TAS2R 
agonist- induced increases in the amplitude of baseline responses TAS2R-agonist mediated inhibitions of 
contractions by C) carbachol- and D) α,β-methylene-ATP. TAS2R agonists (100µM) were administrated 15-
minutes before the evaluations of contractile responses. Data are presented as mean ± SEM.  
Complementary studies in detrusor smooth muscle confirmed that contractions induced by 
carbachol and α,β-methylene ATP were largely dependent on the influx of extracellular Ca2+ 
via L-type Ca
2+
 channels, as these contractions were abolished in the presence of 10 µM 
nifedipine [137, 138]. Moreover, nifedipine prevented the TAS2R agonist-induced increases 
in myogenic activity.  
The data in detrusor smooth muscle indicate that TAS2R agonists interact with at least two 
different signalling pathways. The TAS2R agonist-mediated inhibitions of muscarinic 
contractions probably reflect the same mechanism(s) that are responsible for the relaxation in 
airway and vascular smooth muscle. In addition, TAS2R agonists were shown to enhance 
myogenic activity, which highlights an interaction with another pathway that controls 
membrane depolarisation. 
 
 
 
 
 
26 
 
4.1.6 Summary  
The scheme below provides a summary of the effects of the TAS2R agonists that were 
observed following the different pre-contractions in smooth muscle. 
Figure 10: Overview of the effects of TAS2R agonists on the different pre-contractions in smooth muscle. 
Green indicates a profound inhibition of contractions or a strong relaxation. Red indicates no inhibitory effect. 
Yellow indicates a reduced relaxation/inhibition in relation to the inhibitions seen by the same TAS2R agonists 
within that particular smooth muscle tissue.  
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4.2 MECHANISMS UNDERLYING SMOOTH MUSCLE RELAXATION 
Different pathways have been proposed to underlie the mechanism(s) of TAS2R agonist-
induced bronchorelaxation. These mechanisms are presented in Figure 12 and discussed 
below in relation to our own observations and those made by others. 
4.2.1 Cyclic nucleotides (cAMP/cGMP) 
Asthma therapies, such as β2-adrenoceptor agonists or theophylline, induce bronchodilation 
by increasing the production of cAMP or reducing the degradation of cyclic nucleotides 
(cAMP and cGMP). As TAS2R agonists have been suggested to exert their effects via 
modulation of cyclic nucleotides [139, 140], possible interactions between TAS2R agonists 
and cyclic nucleotides were evaluated in the airway smooth muscle.  
Denatonium-induced relaxations were examined in the presence of blockers of protein kinase 
A and G. The responses to denatonium were not affected by PKA or PKG blockers indicating 
that the downstream effector pathways of cAMP and cGMP are not required for the 
relaxations (Paper I, figure 6D). A similar finding has been observed for chloroquine, which 
failed to activate PKA in HASM cells [67]. In addition, we measured the production of 
cAMP in guinea pig trachea using an ELISA. Administration of the β2-adrenoceptor agonist 
salbutamol as a positive control strongly increased cAMP levels in the trachea. In contrast, 
denatonium and chloroquine failed to raise cAMP levels (Paper I, figure 6E). Taken 
together, these findings indicate that TAS2R agonists elicit bronchorelaxation independently 
of cyclic nucleotides.  
4.2.2 Hyperpolarization via BK channels  
Deshpande and colleagues hypothesised that hyperpolarisation via opening of large 
conductance Ca
2+ 
activated K
+
 (BK) channels could induce relaxation of the airway smooth 
muscle via localised Ca
2+ 
release [67].  
To study the involvement of BK channels in TAS2R-agonist mediated relaxations, sections 
of guinea pig trachea were pre-treated with pharmacological blockers of BK channels; 
iberiotoxin, charybdotoxin and paxillin. Chloroquine-induced relaxations were not affected 
by the presence of BK blockers. On the other hand, relaxations induced by denatonium, as 
well as salbutamol, were decreased in potency following treatment with BK blockers (Paper 
I, figure 6A-C). These initial experiments suggested that BK channels were required in part 
for relaxations occurring due to denatonium and salbutamol. However, we also observed that 
the blockade of BK channels resulted in stronger pre-contractions [141]. Additional 
experiments demonstrated that stronger pre-contractions alone can decrease the potency of 
denatonium and salbutamol in the guinea pig trachea (Paper I, figure 7). This indicates that 
the apparent inhibition of denatonium-induced relaxations by BK channel blockers was a 
consequence of the increased level of pre-contraction, rather than an effect of the BK channel 
itself. We and others have therefore concluded that BK channels are not critical for the 
relaxation induced by TAS2R agonists [142-145].    
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4.2.3 Localised induction of intracellular Ca2+ 
In their initial study, Deshpande et al showed that millimolar concentrations of TAS2R 
agonists were able to increase intracellular Ca
2+
 levels in HASM cells to a similar degree as 
common spasmogens such as bradykinin and histamine [67]. However, others could detect 
only minor, or no increases at all, in intracellular Ca
2+
 following the administration of 
millimolar concentrations of TAS2R agonists in HASM cells or mouse precision-cut lung 
slices (PCLS) [130, 135]. Moreover, although relatively high concentrations (10-100 µM) of 
TAS2R agonists were required to achieve complete relaxations of human and animal airways, 
these concentrations were still markedly lower than the millimolar concentrations that were 
required to increase intracellular Ca
2+ 
levels in HASM cells. Therefore it is unlikely that the 
observed bronchorelaxation due to TAS2R agonists is the result of an induction of 
intracellular Ca
2+
.    
4.2.4 Inhibition of bronchoconstrictor-induced Ca2+ induction 
As mobilisation of intracellular Ca
2+
 is critical for the induction and maintenance of smooth 
muscle contraction in general, it was considered plausible that TAS2R agonists elicit 
relaxation by inhibiting the bronchoconstrictor-induced mobilisation of intracellular Ca
2+
 in 
HASM cells [130, 135]. The effects of different TAS2R agonists on the histamine-induced 
mobilisation of intracellular Ca
2+ 
were therefore examined in HASM cells. The TAS2R 
agonists chloroquine, denatonium, dextromethorphan and quercetin were selected for these 
investigations, because these agonists induced relaxations in human airways that were pre-
contracted by histamine.   
Following a thirty-second baseline measurement, the addition of histamine caused a rapid 
increase in intracellular Ca
2+
 in HASM cells. This increase in intracellular Ca
2+
 peaked after 
fifteen seconds and then slowly returned to baseline. HASM cells were pre-treated with 
TAS2R agonists or vehicle for 5-minutes before this measurement. Chloroquine prevented 
this histamine-induced mobilisation of intracellular Ca
2+
 in a concentration-dependent 
manner (Figure 11). It is noteworthy, that chloroquine relaxed the human bronchi at the same 
concentrations that inhibited Ca
2+
 fluxes in HASM cells. Similarly, quercetin also inhibited 
mobilisation of intracellular Ca
2+
 to an extent that was comparable to the relaxations observed 
in human airways (Figure 11).  
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In contrast, dextromethorphan and noscapine, agonists that relaxed human bronchi well, only 
modestly inhibited the mobilisation of intracellular Ca
2+
 in HASM cells (Figure 11). It may 
be that the time of pre-incubation was not sufficient to reveal an inhibition, and it is therefore 
a limitation that the effects of longer pre-incubation times with the TAS2R agonists were not 
assessed in this study. However, our data in human bronchi demonstrated that these TAS2R 
agonists induce relaxations within 5-minutes of exposure. Therefore, the observed inhibitions 
of intracellular Ca
2+
 mobilisation in HASM cells do not seem to explain the 
bronchorelaxation that these agonists elicit in human bronchi. Taken together, these studies 
demonstrate the distinct inhibitory actions of TAS2R agonist on intracellular Ca
2+
 
mobilisation in HASM cells, indicating that TAS2R agonists do not induce bronchorelaxation 
via one common mechanism.   
Figure 11: Histamine-induced mobilisation of intracellular Ca
2+
 in HASM cells measured by Fluo-4 in the 
presence of TAS2R agonists, the L-type Ca
2+
 channel blocker nifedipine, the β2-adrenoceptor agonist formoterol 
and the phosphodiesterase inhibitor theophylline. Increases in intracellular Ca
2+ 
were presented as percentile 
increase of baseline. Data for each time-point were obtained from 200-400 cells. Arrows: indications for which 
component of the induction (the initiation phase or the sustained phase) of intracellular Ca
2+
 is inhibited. 
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Moreover, different components of the histamine-induced mobilisation of intracellular Ca
2+
 
were decreased by the different TAS2R agonists tested. Chloroquine inhibited the initial 
phase of the Ca
2+
 mobilisation, whereas quercetin predominantly decreased the later stage of 
the intracellular Ca
2+
 mobilisation (Figure 11, arrows). This distinction is most clearly 
exemplified by comparing the inhibitions caused by chloroquine (30 µM) and quercetin (100 
µM).  At these concentrations the two agonists decreased the maximal induction of 
intracellular Ca
2+
 to a similar degree, but the time to the peak of the Ca
2+
 induction was only 
reduced by chloroquine. Similarly to quercetin, dextromethorphan specifically inhibited the 
later phase of the calcium mobilisation that seemed to be critical for the sustainment of 
intracellular Ca
2+ 
(Figure 11, arrows). 
Histamine has been shown to induce mobilisation of intracellular Ca
2+
 in HASM cells 
through IP3, and to sustain levels of intracellular Ca
2+
 via the influx of extracellular Ca
2+ 
[146]. The patterns of the inhibitions of intracellular Ca
2+
 mobilisation observed in our study 
therefore provide suggestions for the Ca
2+
-dependent pathways that TAS2R agonists interact 
with. The sustained phase is considered to be dependent on the influx of extracellular Ca
2+
 via 
an L- type Ca
2+
 independent pathway[146]. The latter is confirmed in our study as nifedipine 
had no effects on the histamine-induced mobilisation of intracellular Ca
2+ 
(Figure 11).  
4.2.5 Inhibition of IP3 signalling   
The observation that chloroquine particularly inhibits the initial phase of the  intracellular 
Ca
2+
 mobilisation in HASM cells, suggests that chloroquine interferes with IP3 signalling. 
Although, our own studies did not specifically investigate the effects of chloroquine on IP3 
signalling, there is evidence in the literature that supports such a statement, as Tan and 
colleagues demonstrated that 100 µM of chloroquine inhibited IP3-induced Ca
2+
 release in 
HASM cells [130]. The same authors observed that IP3-induced Ca
2+
 release in HASM cells 
was inhibited by quinine, and to a lesser extent by denatonium [130]. Moreover, studies by 
Misra and colleagues demonstrated that chloroquine- and quinine-mediated inhibitions of IP3 
signalling were caused by a blockade of IP3 receptors and not a decreased synthesis of IP3 
[147].  
Our data in the different smooth muscle preparations demonstrated that chloroquine 
consistently inhibited contractions induced by agonists of G-protein coupled receptors (Paper 
I and II). Because all of these agonists depend on IP3-induced Ca
2+ 
for their contractions, it is 
plausible that chloroquine exerts its effects in smooth muscle via an inhibition of IP3 
signalling. This mechanism could be also valid for the structurally related TAS2R agonist 
quinine, as its potency for IP3 inhibition in HASM cells was comparable to the effect of 
quinine in airway smooth muscle [130]. On the other hand, the data from Tan and colleagues 
showing that denatonium inhibited IP3 signalling [130], are more difficult to link to our 
observations in airway smooth muscle, as denatonium failed to relax contractions induced by 
histamine in the guinea pig trachea.  
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In addition, our experiments in HASM cells showed that both chloroquine and the β2-
adrenoceptor agonist formoterol prolonged the time to peak for the induction of intracellular 
Ca
2+ 
in HASM cells (Figure 11). The observed effects of formoterol on IP3 signalling are in 
line with previous reports that have shown that β2-adrenoceptor agonists can reduce IP3 
synthesis or inhibit IP3 signalling via cAMP and PKA [63, 148]. Overall, it can be concluded 
that chloroquine and quinine presumably relax airway smooth muscle by inhibiting IP3 
signalling, but this mechanisms does not apply to all TAS2R agonists.  
4.2.6 Inhibition of L-type Ca2+ channels 
An alternative mechanism proposed to be responsible for TAS2R-mediated relaxations is that 
TAS2R agonists inactivate voltage-dependent L-type Ca
2+
 channels [135]. 
To test this hypothesis, we assessed the potential L-type blocking activities of the different 
TAS2R agonists using potassium chloride-mediated contractions in the guinea pig trachea, a 
functional assay that was shown to be sensitive to the action of the L-type Ca
2+
 channel 
blocker nifedipine. Contractions induced by potassium chloride were prevented by 
dextromethorphan and quinine, whereas noscapine induced only minor inhibitions of the 
potassium-induced contractions, and denatonium and chloroquine were without effects in this 
assay (Paper II, figure 3B). These experiments indicated that chloroquine and denatonium 
do not exert L-type blocking activities at a concentration that was sufficient to induce 
relaxations of airway smooth muscle. On the other hand, dextromethorphan and quinine may 
act as inhibitors of L-type channels.   
Our follow-up investigations in the guinea pig aorta demonstrated that all TAS2R agonists 
elicited complete relaxations of phenylephrine-induced pre-contractions in an experimental 
set-up where L-type channel activities should be completely inhibited (Paper II, figure 3C). 
Although, for certain TAS2R agonists, these observations could be due to antagonism of 
noradrenergic receptors (paragraph 4.2.7.2), the data clearly indicated that the TAS2R 
agonists chloroquine and noscapine also induce relaxation of airway and vascular smooth 
muscle independently of an interaction with L-type channels.  
Dextromethorphan-induced inhibitions of contractions in airway smooth muscle (KCl, 
carbachol, histamine), ileum (histamine, acetylcholine and PGE2) and bladder (carbachol, 
α,β-methylene-ATP) (Figure 10), can be mimicked by nifedipine, suggesting that 
dextromethorphan induces relaxation by inhibiting L-type-Ca
2+ 
channels. However, this 
preliminary conclusion can be questioned by the observation that dextromethorphan failed to 
prevent its own induction of myogenic activity in detrusor smooth muscle, whereas 
nifedipine could. Moreover, our Ca
2+
 mobilisation studies in HASM cells revealed that 
dextromethorphan inhibits a specific component in the induction of intracellular Ca
2+
 that is 
linked to the influx of extracellular Ca
2+ 
[146], but does not require the involvement of L-type 
Ca
2+
 channels (Figure 11). This suggests that dextromethorphan exerts parts of its effects in 
smooth muscle via inhibition of other types of voltage-dependent Ca
2+
 channels [96-98].    
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4.2.7 Antagonism of G-protein coupled receptors 
4.2.7.1 Muscarinic antagonism 
As denatonium selectively relaxed pre-contractions induced by carbachol in airway smooth 
muscle, the question arose as to whether denatonium antagonized muscarinic (M3) receptors. 
However, acetylcholine-induced relaxations in guinea pig aorta, which are dependent on 
muscarinic receptor activation [149], were not affected by denatonium. Moreover, 
denatonium failed to inhibit carbachol-mediated contractions in guinea pig detrusor smooth 
that are dependent on M3 receptor activation [137]. Therefore, the data suggest that 
relaxations caused by denatonium are not due to antagonism of muscarinic receptors, but 
rather are the   consequence of a specific inhibition of the muscarinic excitation-contraction 
coupling process in airway smooth muscle.  
4.2.7.2 Noradrenergic antagonism 
Similarly, TAS2R agonists were shown to selectively relax noradrenergic contractions in 
vascular smooth muscle. The possible antagonism of α-adrenoceptors was therefore evaluated 
in the guinea pig taenia coli, a preparation in which α1-adrenoceptor activation results in 
relaxation [124]. In this assay, denatonium and quinine completely prevented relaxations 
induced by phenylephrine, indicating that the effects of these TAS2R agonists in vascular 
smooth muscle are mediated by antagonism of α-adrenoceptors.   
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4.2.8 Summary on the mechanisms of TAS2R agonists 
Our studies demonstrate that TAS2R agonists do not induce bronchorelaxation via one single 
common pathway involving cAMP/cGMP, BK channels or L-type Ca
2+
 channels. Instead, the 
TAS2R agonists were shown to interact individually with different pathways implicated in 
the mobilisation of Ca
2+ 
from intracellular and extracellular sources. Chloroquine, quercetin 
and quinine seem to relax airway smooth muscle by inhibiting IP3 signalling, whereas 
dextromethorphan may exert its effects via the inhibition of voltage-dependent Ca
2+
 channels. 
The pathways underlying denatonium-, and especially noscapine-, induced responses require 
further investigations.  
 
Figure 14: Summary of proposed pathways for TAS2R-agonist mediated relaxation, interpretation of these 
mechanisms is provided in the text: 
1) Localised induction of intracellular Ca2+ 
2) Hyperpolarization via opening BK channels 
3) Inhibition of bronchoconstrictor-induced mobilisation of intracellular Ca2+ 
4) Inhibition of IP3 signalling 
5) Inhibition of L-type Ca2+ channels 
6) Antagonism of G-protein coupled receptors 
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4.3 REQUIREMENT OF TAS2RS FOR BRONCHORELAXATION  
The critical question that emerges is whether or not the observed actions of TAS2R agonists 
in the airway smooth muscle and other cell-types are mediated via the TAS2Rs. This question 
is particularly relevant as TAS2Rs are low affinity receptors activated by relatively high 
concentrations of TAS2R agonists [78, 150], which increases the possibility that TAS2R 
agonists may interact with other pathways, and exert their effects, including 
bronchorelaxation, via TAS2R-independent pathways.  
The optimal way to assess this would be to investigate whether TAS2R agonists cause 
relaxation of airway smooth muscle from TAS2R-deficient animals, or in the presence of 
antagonists. To our knowledge, only a TAS2R5-deficient mouse has been developed [72] and 
although TAS2R antagonists are under development, no antagonists are currently available 
against the receptors for chloroquine (TAS2R3), denatonium (TAS2R10), dextromethorphan 
(TAS2R1 and TAS2R10), noscapine (TAS2R14) and quercetin (TAS2R14) [151-155].  
Therefore, an alternative two-step strategy was employed to determine TAS2R involvement 
in bronchorelaxation. First, studies were performed that aimed to define conditions that could 
increase/decrease TAS2R expression in HASM cells. Thereafter, the functional consequence 
of modulated TAS2R expression was evaluated by examining TAS2R-agonist mediated 
inhibitions of intracellular Ca
2+
 mobilisation in HASM cells, as this mechanism seems to be 
responsible for TAS2R agonist-induced bronchorelaxation (paragraph 5.2.4).    
4.3.1 Inflammation  
The impact of inflammatory mediators and asthma-mediations on TAS2R expression was 
investigated in HASM cells, as studies have suggested that TAS2R expression is regulated by 
asthmatic inflammation [82]. The mRNA expression of all TAS2Rs was reduced by TNFα 
and dexamethasone, whereas the cytokines IL-13 and TGFβ that are implicated in the 
pathogenesis of asthma did not affect TAS2R expression (Paper 3, table 1).  
Although the functional consequences of these effects were not further investigated in HASM 
cells, our finding that the effects of chloroquine and noscapine in IL-13-treated human 
bronchi are essentially unaltered (Paper 4, figure 3C-D), is in line with the lack of effect of 
IL-13 on TAS2R expression in HASM cells.        
4.3.2 Serum-deprivation 
As studies in cardiomyocytes have suggested that TAS2R expression increases upon 
starvation, the effects of glucose and serum-deprivation on TAS2R expression in HASM cells 
were investigated [85]. In contrast to the results in cardiomyocytes, glucose-deprivation failed 
to affect TAS2R expression in HASM cells. On the other hand, serum-deprivation increased 
the expression of mRNA for TAS2R3, TAS2R4, TAS2R10 and TAS2R14 in HASM cells in 
a time-dependent matter (Paper 3, figure 2). These increases were accompanied by an 
increased expression of the smooth muscle marker α-actin that reflects the serum-deprivation-
induced induction of a more contractile phenotype of cultured HASM cells [156]. 
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Interestingly, our findings are in line with the relatively high TAS2R expression that 
Deshpande and colleagues reported in their HASM cells following 7 days of serum-
deprivation [67].   
When examining the effect of chloroquine on histamine-induced mobilisation of intracellular 
Ca
2+ 
in HASM cells, chloroquine-mediated inhibitions were greater following 48-hours of 
serum deprivation (Paper 3, figure 5). On the other hand, the inhibitions of histamine-
induced mobilisation of intracellular Ca
2+
 by the TAS2R14 agonists noscapine (≈15%) and 
quercetin (≈50%) remained similar in this set-up, despite an increase in TAS2R14 mRNA 
expression.  
Methodological concerns prevent strong conclusions to be drawn from these observations. 
For example, the absence of antibodies prevented us from verifying whether increased 
TAS2R mRNA expression resulted in increased protein expression at the time-points that the 
functional experiments were conducted. Moreover, it is difficult to conclude whether the 
increased effects of chloroquine are a direct consequence of increased TAS2R3 expression, 
or whether they are related to serum-deprivation-induced phenotypic changes in the HASM 
cells.   
4.3.3 siRNA-mediated knock-down of TAS2Rs   
A more selective approach to modulate the expression of TAS2Rs in HASM cells was 
therefore chosen, involving the use of siRNAs. For these investigations, an efficient siRNA 
transfection protocol for HASM cells was developed that decreased MAPK1 mRNA by 79% 
two days-after the initial transfection (Figure 4).     
Attempts to decrease TAS2R3 using pooled and individual siRNAs were ineffective, and 
prevented us from assessing the requirement for TAS2R3 in responses towards chloroquine. 
On the other hand, pooled siRNAs against TAS2R14 reduced TAS2R14 mRNA expression 
in HASM cells by 50% (Paper 3, Figure 6). The efficacy of this TAS2R14-mediated 
knockdown in HASM cells was comparable to recent siRNA attempts at reducing TAS2R1 
[157], and higher than the 35% reduction for TAS2R10 reported by Deshpande et al, when 
the function of TAS2Rs in HASM cells was first described [67].    
Functional measurements were conducted one day after the evaluation of mRNA knock-
down, in order to allow any effect on TAS2R14 protein to become apparent. In these 
experiments, quercetin-mediated inhibitions of intracellular Ca
2+
 mobilisation were no 
different between mock, negative siRNA and TAS2R14 siRNA treated HASM cells (Paper 
III, figure 7).  Although it is possible that TAS2R expression is regulated by mechanisms 
other than  transcription, the data suggest that TAS2R14 is not critical for the effects of the 
TAS2R14 agonist quercetin on Ca
2+
 mobilisation in HASM cells [150]. 
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4.4 AIRWAY HYPERREACTIVITY TO IL-13 
4.4.1 Human bronchi - potency 
To investigate the effects of IL-13 on airway smooth muscle function in intact human small 
airways, contractile and relaxant responses were assessed in paired human bronchial rings 
that were cultured for two days in the presence or absence of IL-13. IL-13 profoundly 
increased the potencies of the spasmogens histamine (3.1-fold) and carbachol (2.5-fold) in 
intact human small airways (Paper IV, figure 1). These findings confirm and extend 
previous observations made in precision-cut lung slices (PCLS) of human small airways, 
where in a limited study, IL-13 was shown to increase the potency of carbachol [121]. 
4.4.2 Human bronchi - amplitude 
To examine whether IL-13 affected the amplitude of contractile responses in the human 
bronchi, a novel re-culture procedure for human bronchial rings was developed, enabling 
assessment of the impact of IL-13 on individual bronchial rings. In this re-culture assay, we 
evaluated contractile responses towards KCl and histamine in untreated human bronchial 
rings on Day 1. After an extensive wash-out, these same bronchial rings were transferred 
back into culture and divided into two groups, one treated with a vehicle control and the other 
with IL-13. Following two-days of culture, contractile responses towards KCl and histamine 
were re-assessed in these bronchial segments (Day 3). The main advantage of this re-culture 
assay compared to investigations using paired bronchial segments, is that the outcome cannot 
be biased by variations in inner diameter, length and the organization and amount of airway 
smooth muscle in the bronchial segments.  
The re-culture procedure itself did not affect the amplitude of contraction, as the contractions 
towards KCl and histamine in the bronchi of the vehicle group were similar in magnitude 
before (day 1) and after the re-culture period (day 3) (Paper IV, figure 2). Neither were the 
maximal contractions induced by KCl and histamine changed after the period of re-culture 
with IL-13 (Paper IV, figure 2). Nonetheless, in this assay the administration of IL-13 did 
result in an increased potency of histamine, indicating that IL-13 specifically increases the 
potency and not the amplitude of contractile responses in intact human airways (Figure 13).   
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Figure 13: Cumulative concentration-responses towards histamine in human bronchial rings that did not receive 
any treatment (Day 1) or following a two day re-culture period during which the same bronchial rings were 
treated with vehicle or IL-13 (100ng/ml). Data are presented as mean ± SEM (n=15).  
Our findings regarding the effects of IL-13 in human small airways differ from previous 
observations made in the airway smooth muscle of mice and rabbits, where IL-13 primarily 
increased the amplitude and not the potency of contractile responses [113-116]. These studies 
were however conducted in tracheal smooth muscle, which may explain the different results, 
because the excitation-contraction coupling is markedly different between bronchial and 
tracheal smooth muscle [158]. However, in the smaller airways of the mouse, IL-13 also 
increases only the amplitude, and not the potency of contractile agonists [159], indicating that 
IL-13 induces similar changes along the airway smooth muscle of the respiratory tree. 
Therefore, the discrepancies between the observed effects of IL-13 in animal airways 
(amplitude) and human airways (potency) must be a consequence of species differences and 
possibly implicate different mechanisms.   
4.4.3 Mobilisation of intracellular Ca2+ 
Airway smooth muscle contraction is initiated by agonist-induced mobilisation of 
intracellular Ca
2+ 
 [61], which has encouraged studies to examine the effects of IL-13 on 
intracellular Ca
2+
 mobilisation in HASM cells. These studies have shown that IL-13 can 
enhance the maximal induction of  intracellular Ca
2+
 by different spasmogens in HASM cells, 
thereby providing a plausible mechanism for the IL-13-induced increase in the amplitude of 
contractions in intact airway smooth muscle [114, 129, 159-161].  
However, previous studies have not investigated whether IL-13 also changes the potency of 
agonist-induced intracellular Ca
2+
 mobilisation in HASM cells. Therefore, we decided to 
study the consequences of IL-13 on the concentration-dependent mobilisation of intracellular 
Ca
2+
 in HASM cells. These studies clearly showed that IL-13 also increases the potency of 
histamine-induced intracellular Ca
2+ 
mobilisation in HASM cells (Paper IV, figure 4), 
strongly supporting the view that a lower threshold for the mobilisation of  intracellular Ca
2+
 
in HASM cells is responsible for the IL-13-induced increase in potency of histamine in intact 
human airways.  
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4.4.4 Mechanisms underlying IL-13 induced-responses 
Different pathways have been implicated in the effects of IL-13 in airway smooth muscle. 
This work did not permit in-depth studies to uncover the mechanisms underlying IL-13-
induced hyperreactivity in the human bronchi. Therefore a summary of possible mechanisms 
in relation to our findings is discussed below and presented schematically in (Figure 14). 
As discussed in the previous paragraph, IL-13 increases both the threshold and maximal 
mobilisation of intracellular Ca
2+
 in HASM cells (1). However, the pathway(s) that IL-13 
utilises to increase the mobilisation of Ca
2+
 in HASM cells remain undefined. One possibility 
is that IL-13 increases the expression of the G-protein coupled receptors for the different 
spasmogens (2), which has been demonstrated for the CysLT1 [162] and H1 receptor [160, 
163]. An increased receptor expression would result in more IP3 formation and probably 
facilitate a greater influx of Ca
2+
 from intracellular pools and thus explain our effects in 
HASM cells.  
Another pathway that has been linked to intracellular Ca
2+ 
mobilisation in HASM cells is the 
CD38 /cyclic adenosine diphosphate ribose (cADPR) pathway (3). In HASM cells, IL-13 was 
shown to increase CD38 expression which controls the signalling molecule cADPR that 
mobilises Ca
2+
 via ryanodine channels [129]. This IL-13-induced induction of CD38 was 
shown to be sensitive to glucocorticoids [164]. However, as our studies demonstrated that 
dexamethasone failed to prevent the IL-13-induced hyperreactivity of human bronchi and 
HASM cells (Paper IV, figure 5), it is unlikely that CD38 is crucial for the IL-13-induced 
airway hyperreactivity.   
IL-13 has been suggested to augment airway smooth muscle contraction via a Ca
2+ 
independent pathway that involves Ca
2+
 sensitisation (4), as IL-13 increases RhoA expression 
[115]. RhoA can activate Rho kinases, which in their turn maintain contractions by 
inactivating/inhibiting the myosin light chain phosphatases (MLCP) in airway smooth muscle 
[165]. Further investigations in human bronchi should assess the involvement of Rho-kinase 
in IL-13-induced airway hyperreactivity.  
One question that evolves from our findings is why IL-13 particularly affected the potency, 
and not the amplitude of contractions in the human bronchi, as previous studies have mainly 
observed effects on the amplitude of responses. To answer this question, it is important to 
emphasize that contractions are the end-result of a consecutive series of signalling events that 
are required for excitation-contraction coupling [40, 57]. Thus, although receptor number, the 
degree of IP3 synthesis and the levels of intracellular Ca
2+
 are important in this series of 
events, the outcome or amplitude of contraction is still dependent of the rate-limiting steps of 
the system, which in this case are the down-stream effectors of contraction; calmodulin, actin 
and myosin. However, an increased receptor expression in a tissue that already contains a 
high density of receptors could induce a potency shift, rather than a change in amplitude 
[166]. This phenomenon has been demonstrated for the H1 receptor in airway smooth muscle 
[167]. Therefore, the increased potency and maximal mobilisation of intracellular Ca
2+
 in 
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HASM cells, could explain why we observe an IL-13-induced increase in the potency of 
contractions in the human bronchus.  
 
 
Figure 14: Proposed pathways via which IL-13 induces hyperreactivity of airway smooth muscle.  
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5 CONCLUSIONS 
 
The main conclusions from this thesis are: 
 
o TAS2R agonists induce strong relaxations in guinea pig, mouse and human airways 
that vary depending on the agonist used for pre-contraction. 
  
o TAS2R agonists exhibit strong inhibitory actions in vascular, gastrointestinal and 
detrusor smooth muscle, indicating that the effects of TAS2R agonists are not 
restricted to airway smooth muscle.  
 
o TAS2R agonists induce bronchorelaxation via distinct pathways, as they each inhibit 
specific components of the bronchoconstrictor-induced mobilisation of intracellular 
Ca
2+ 
that reflect different pathways of Ca
2+
 entry. 
 
o The involvement of TAS2Rs in the effects of TAS2R agonists on smooth muscle can 
be questioned because: 
o TAS2R agonists exhibit different responses when  pre-contractions are induced via 
the TP receptor. 
o TAS2R agonists distinctly affect histamine-induced mobilisation of Ca2+ 
o Agonists for the same receptor (TAS2R14) exert different effects. 
o Responses by TAS2R14 agonists remain unchanged despite altered TAS2R 
expression. 
 
o IL-13 induces hyperreactivity of intact human airways by increasing the sensitivity of 
airway smooth muscle cells to bronchoconstrictor-induced Ca
2+
 mobilisation. This 
study indicates that functional remodelling of the airway smooth muscle can 
contribute to airway hyperresponsiveness.      
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6 GENERAL DISCUSSION 
The airway smooth muscle is a major contributor to the pathogenesis of asthma due to its 
involvement in airway obstruction and AHR. Targeting the airway smooth muscle to achieve 
bronchorelaxation via different pathways has therefore been an attractive therapeutic strategy 
for relieving asthma symptoms. The activation of relaxant pathways, via β2-adrenoceptor 
agonists (and in certain cases theophylline), the antagonism of contractile receptors (CysLT1, 
M3) on the airway smooth muscle [168-170], as well reducing the amount of airway smooth 
muscle via bronchial thermoplasty [171] have all demonstrated clinical benefit for patients 
with asthma. Nonetheless, there remains an unmet need for new therapeutic 
bronchorelaxants, as patients with severe asthma may still experience severe airway 
obstruction, despite the use of high doses of glucocorticoids and a mix of short- and long-
acting β2-adrenoceptor agonists. 
“Bitter treats for better breathing?” This question is derived from the initial work by 
Deshpande et al which suggested that TAS2Rs might be a potential novel target on the 
airway smooth muscle as TAS2R agonists were shown to induce efficacious relaxation [67, 
172].  The aim of this thesis was to define the pharmacological actions of TAS2R agonists in 
(airway) smooth muscle and determine the potential of TAS2Rs and their agonists as new 
therapeutic agents for asthma.  
To investigate the effects of TAS2R agonists on airway smooth muscle function,  the guinea 
pig trachea was chosen as an experimental model, because the receptor pharmacology of the 
guinea pig closely resembles that of human airways [128]. By using a selection of defined 
TAS2R agonists [78], our studies demonstrated that TAS2R agonists are strong, but not 
potent, relaxants of airway smooth muscle (Paper I-II). These observations were 
subsequently confirmed in intact human airways both by ourselves and others (Paper III- 
IV) [144], thereby supporting the potential of TAS2R agonists as bronchorelaxants.    
One requirement for a potential novel bronchorelaxant is that it should induce a strong 
bronchorelaxation that is not influenced by environmental factors such as increased bronchial 
tone or inflammation. In this aspect, our data in the guinea pig, as well as human bronchi, 
demonstrate that under conditions when responses to the short-acting β2-adrenoceptor agonist 
salbutamol are impaired, for instance under high tone (Paper I) or during IL-13 induced 
inflammation (Paper IV), TAS2R agonists can induce a more efficacious relaxation than the 
commonly used β2-adrenoceptor agonists.  
The strong responses that TAS2R agonists display in smooth muscle preparations are 
themselves of great interest, particularly as their relaxations were shown not to be a 
consequence of muscarinic antagonism, activation of BK channels, or earlier described 
pathways of relaxation that involve cAMP, PKA or PKG (Paper I). Instead, our data in 
HASM cells clearly demonstrate that TAS2R agonists can decrease the mobilisation of 
intracellular Ca
2+
 induced by contractile agonists (Paper III). These data provide support for 
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previous data showing that inhibition of IP3 signalling could be an important pathway that is 
affected by TAS2R agonists[130]. However, this pathway is not affected by all TAS2R 
agonists, as noscapine exhibited only minor effects on intracellular Ca
2+ 
mobilisation, 
whereas dextromethorphan seemed to inhibit the entry of extracellular Ca
2+
 (Paper III). 
Irrespective of whether the effects of TAS2R agonists are mediated via the TAS2Rs or not, 
these undefined pathways of relaxation alone present new potential targets for 
bronchorelaxation.    
The involvement of TAS2Rs in the effects induced by TAS2R agonists is not currently easily 
evaluated, as gene-deficient animals and antagonists for the receptors of the TAS2R agonists 
are lacking. However, to circumvent these issues, we used the strategy of selectively 
decreasing the expression of TAS2R14 with siRNA and then examining possible effects on 
the inhibition of intracellular Ca
2+
 mobilisation in HASM cells caused by the TAS2R14 
agonist quercetin. However, a reduction in TAS2R14 mRNA expression did not affect the 
inhibitory effects of quercetin in HASM cells (Paper III). Although these data suggest that 
TAS2R14 is not critical for the effects of quercetin, no firm conclusions can yet be drawn 
from these experiments, as we did not confirm that the siRNA-induced reduction of 
TAS2R14 mRNA also resulted in decreased protein levels.  
Indirect evidence presented in this thesis does suggest that the TAS2R agonists elicit 
bronchorelaxation independently of TAS2R activation. This preliminary conclusion is based 
on the observations that the relaxations induced by TAS2R agonists are not mediated via a 
common pathway, as TAS2R agonists differently relax TP-receptor mediated contractions 
(Paper I and II) and distinctly inhibited the mobilisation of intracellular Ca
2+ 
 (Paper III). In 
addition, noscapine and quercetin, which both act on TAS2R14, differently inhibited the 
mobilisation of intracellular Ca
2+
 in HASM cells (Paper III). Furthermore, our statement 
regarding the lack of TAS2R involvement is supported by the recent observation that 
chloroquine inhibited the contractility of the mouse heart via a G-protein independent 
pathway [86]. Of relevance is also the finding that TAS2R agonists exert effects in cells that 
do not express TAS2Rs, for instance in the amoeba Dictyostelium [173]. Therefore, it would 
be of great interest to study responses towards TAS2R agonists in gene-deficient mice 
lacking α-gustducin, the G-protein assumed to be required for TAS2R signalling [73], as such 
investigations would allow more definitive conclusions to be drawn regarding the 
contribution of TAS2Rs to TAS2R agonist-induced bronchorelaxation.   
Until TAS2R-deficient animals are developed, the tools available to explore the oral, and 
proposed extra-oral functions of TAS2Rs will be heavily dependent on the TAS2R agonists. 
Although the activities of the TAS2R agonists have been carefully characterized in TAS2R-
overexpressing HEK-293 cells [78, 150], their use at relatively high concentrations increases 
the risk of interaction with TAS2R-independent pathways. Thus, in the absence of TAS2R 
antagonists, caution is warranted when the experimental effects of TAS2R agonists observed 
in cells/tissues are directly extrapolated to the biological functions of the TAS2Rs. Instead, 
the pharmacological analysis of the effects of the TAS2R agonists and their possible 
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interactions with TAS2R-dependent/independent pathways as presented in this thesis (Paper 
I-III), may serve as a guide for future investigations that intend to define the biological 
functions of TAS2Rs and their related agonists. 
The last part of this thesis relates to the role of the airway smooth muscle in the development 
of AHR. Although the importance of the airway smooth muscle in AHR is undisputed, the 
mechanisms in airway smooth muscle that promote exaggerated airway narrowing remain 
unclear [30, 42, 52, 55].  The remodelling of the airways in asthma is thought to involve 
hyperplasia and hypertrophy of airway smooth muscle cells, but it is also possible that the 
intrinsic contractile properties of the airway smooth muscle are “remodelled” as a 
consequence of the inflammatory environment. Most of the data supporting such a role have 
been obtained from studies in cultured HASM cells and animal airways [30, 55]. However, 
such a phenomenon has only sparsely been investigated in humans, and if so, the proposed 
effects of certain mediators (e.g. TLR3) could not be reproduced in human airways [121].  
Our study addressed the question of whether IL-13 could alter airway smooth muscle 
function in intact human airways, as IL-13 has been implicated in the development of 
hyperreactivity in animal airway smooth muscle [113-115, 117, 159]. Our investigations in 
human small airways clearly demonstrated that IL-13 can increase the potency of common 
spasmogens and thus induce direct hyperreactivity of the airway smooth muscle (Paper IV). 
This study is therefore unique as it is one the first studies to prove that inflammation (IL-13) 
can indeed alter the intrinsic contractile properties of intact human airway smooth muscle.  
Our study primarily demonstrated the existence of IL-13-induced hyperreactivity in human 
airways, yet the mechanisms underlying this phenomenon remain incompletely understood. It 
would be important to investigate the involvement of different components of the IL-13 
signalling pathway and assess whether the observed effects are dependent on activation of the 
IL-4Rα/IL-13Rα1 receptor complex and STAT-6 phosphorylation. Such investigations would 
also increase our understanding of why the glucocorticoid dexamethasone failed to prevent 
IL-13-induced hyperreactivity in both human bronchi and HASM cells (Paper IV), as one 
possible explanation is that glucocorticoids do not affect STAT-6 signalling [174]. 
Furthermore, it will be essential to determine the mechanisms involved in the IL-13-induced 
increases in contraction potency in human bronchi, and mobilisation of Ca
2+
 in HASM cells. 
One strategy to achieve this would be to perform microarrays in IL-13-treated human bronchi 
and HASM cells in parallel, in order to define mutual effector protein(s) that induce 
hyperreactivity in both human bronchi and HASM cells. 
Finally we ask, what is the clinical importance of our findings? To answer this question we 
have to consider the source of IL-13, as IL-13 is not solely produced by Th2 cells but also in 
significant amounts by mast cells [175]. Mast cells infiltrate the airway smooth muscle of 
patients with asthma [13] and their numbers within the airway smooth muscle correlate 
significantly with AHR [176]. This raises the possibility that localized IL-13 release from 
mast cells in close proximity to airway smooth muscle cells could induce hyperreactivity of 
the latter, and thus contribute to AHR. Notably, patients with eosinophilic bronchitis 
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displayed increased airway smooth muscle mass in the absence of AHR, indicating that AHR 
is not simply a consequence of increased airway smooth muscle mass [176]. Instead, these 
data suggest that inflammation causes a phenotypic alteration of airway smooth muscle cells 
which, in contrast to the morphologically apparent increase in cell growth, affects their 
function. In this thesis we propose the term “functional remodelling” to describe this process. 
With respect to the observed IL-13-induced shifts in the potency of common spasmogens, it 
is important to emphasize that relatively small potency changes can result in profound effects 
in vivo, as airway resistance is inversely related to the 4
th
 power of the airway radius [177]. 
One query that needs to be addressed is whether the effects of IL-13 on the potencies of 
individual spasmogens are additive when the mediators are released together, for instance 
during the antigen-induced response, as this would provide more information on the maximal 
capacity of this IL-13-induced hyperreactivity. 
There are certainly other pathways that contribute to AHR as well, but our data demonstrating 
that IL-13 induces functional remodelling of intact human airways, suggests that 
inflammation-induced alterations of the airway smooth muscle can contribute to AHR. 
Importantly, IL-13 is only one of the mediators released in the inflammatory environment of 
the airways in asthma. Thus, these data introduce the possibility that other mediators, alone or 
in combination, could have similar effects to IL-13, causing airway smooth muscle 
hyperreactivity and the development of AHR.  
This thesis aimed to define the potential of the TAS2Rs and IL-13, in relation to their effects 
on the airway smooth muscle, to be targets for the development of future asthma therapies. 
Although, the importance of the TAS2Rs may be questioned, the strong actions of bitter 
tastants on smooth muscle function are undisputed and therefore warrant further 
investigations into their efficacious and intriguing pathways of relaxation. On the other hand, 
IL-13 was clearly shown to induce functional remodelling of the ASM in human airways that 
can contribute to the phenomenon of airway hyperresponsiveness.   
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7 POPULAR SUMMARY 
Asthma is a disease of the airways in the lungs that affects more than 300 million people 
worldwide. The life-time risk of developing asthma life is around 35%, but most people 
develop the disease during childhood. Patients who have asthma experience symptoms of 
cough and shortness of breath, which result in breathing difficulties. These problems are 
caused by inflammation of the airways, which causes the smooth muscle layer around the 
airways to constrict (bronchoconstriction). This bronchoconstriction impairs the flow of air 
through the airways and causes the periods of shortness of breath. The airways of patients 
with asthma are also hypersensitive, as their airways can constrict in reaction to 
environmental factors (like cold air or tobacco smoke), which normally have no effect in 
healthy individuals. This phenomenon is called “airway hyperresponsiveness”.  
As patients often suffer from asthma for long periods of their lives, it is important that they 
receive good treatments to control the symptoms of their disease. Asthma therapy is focused 
on the control and relief of symptoms. Airway inflammation is controlled to prevent the long 
term effect of lung injury (using drugs called glucocorticoids). In case of an asthma attack, 
short-acting drugs (relaxants) can be used immediately to relieve the symptoms by reversing 
constriction of the airway smooth muscle. Although relaxants of the airway smooth muscle 
have been very successful in the treatment of asthma, patients with the most severe asthma do 
not always benefit from these treatments. There is therefore a need for new drugs to relax the 
airway smooth muscle.  
In order to develop new treatment strategies for asthma, research aims to find new drug 
targets. A target of interest is the bitter taste receptors. These receptors (TAS2Rs) that allow 
us to sense the taste of bitter on our tongues, have also been found on airway smooth muscle 
cells. It is proposed that bitter substances relax airway smooth muscle via these receptors. 
The first part of this thesis investigated the effects of bitter substances on the airway smooth 
muscle, in order to evaluate their potential in the future treatment of asthma.   
We found that many bitter substances relax the airway smooth muscle of humans, mice and 
guinea pigs. This was the case for quinine (the bitter component of tonic water), denatonium 
(used to prevent thumb sucking), dextromethorphan and noscapine (the latter both found in 
cough medicine). The contractions of airway smooth muscle depend on increases in 
intracellular calcium and we found that the bitter tastants reduce intracellular calcium in 
different ways. The pathways that caused the relaxation of airway smooth muscle were also 
found to be different from previously known pathways. This indicates that new pathways 
might be involved in the effects of the bitter tastants, and suggests that the bitter tastants 
might even relax the airway smooth muscle independently of TAS2Rs. Nonetheless, bitter 
tastants are strong relaxants in airway smooth muscle, presumably via novel pathways that 
warrant further investigation.  
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The last study of this thesis focused on the question of why the airways of patients with 
asthma are hypersensitive (airway hyperresponsiveness). One possible explanation for this 
phenomenon is that the inflammatory environment of the asthmatic airway changes the way 
in which the airway smooth muscle contracts. This hypothesis was tested in the lab by 
stimulating isolated human airways with interleukin-13 (IL-13), an important pro-
inflammatory substance in asthma. Our experiments showed that human airways exposed to 
IL-13 contracted more easily. This indicates that inflammation can indeed alter the properties 
of airway smooth muscle and provides a possible explanation for why the airways of patients 
with asthma are hypersensitive.   
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